G1 Therapeutics Inc has a consensus price target of $15.71, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from Needham, Wedbush, and Needham on February 28, 2024, February 13, 2024, and February 13, 2024. With an average price target of $9.33 between Needham, Wedbush, and Needham, there's an implied 111.64% upside for G1 Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/28/2024 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 172.11% | Needham | Gil Blum | → $12 | Reiterates | Buy → Buy | Get Alert |
02/13/2024 | GTHX | Buy Now | G1 Therapeutics | $4.41 | -9.3% | Wedbush | David Nierengarten | $5 → $4 | Maintains | Outperform | Get Alert |
02/13/2024 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 172.11% | Needham | Gil Blum | $14 → $12 | Maintains | Buy | Get Alert |
01/24/2024 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 217.46% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
12/06/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 217.46% | Needham | Gil Blum | → $14 | Reiterates | Buy → Buy | Get Alert |
10/30/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 13.38% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
10/06/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | — | JP Morgan | Anupam Rama | — | Downgrade | Neutral → Underweight | Get Alert |
08/03/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 13.38% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
08/03/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 149.43% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
08/02/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 330.84% | EF Hutton | Tony Butler | → $19 | Reiterates | → Buy | Get Alert |
08/02/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 217.46% | Needham | Gil Blum | $18 → $14 | Maintains | Buy | Get Alert |
06/26/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 149.43% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
06/05/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 149.43% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | Buy → Buy | Get Alert |
06/05/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 308.16% | Needham | Gil Blum | → $18 | Reiterates | Buy → Buy | Get Alert |
05/04/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 149.43% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
05/04/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 81.41% | Raymond James | Dane Leone | $24 → $8 | Maintains | Outperform | Get Alert |
04/19/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 308.16% | Needham | Gil Blum | → $18 | Reiterates | → Buy | Get Alert |
03/02/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 149.43% | HC Wainwright & Co. | Edward White | → $11 | Reiterates | → Buy | Get Alert |
02/14/2023 | GTHX | Buy Now | G1 Therapeutics | $4.41 | 308.16% | Needham | Gil Blum | $31 → $18 | Maintains | Buy | Get Alert |
The latest price target for G1 Therapeutics (NASDAQ: GTHX) was reported by Needham on February 28, 2024. The analyst firm set a price target for $12.00 expecting GTHX to rise to within 12 months (a possible 172.11% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for G1 Therapeutics (NASDAQ: GTHX) was provided by Needham, and G1 Therapeutics reiterated their buy rating.
The last upgrade for G1 Therapeutics Inc happened on January 30, 2023 when JP Morgan raised their price target to $10. JP Morgan previously had an underweight for G1 Therapeutics Inc.
The last downgrade for G1 Therapeutics Inc happened on October 6, 2023 when JP Morgan changed their price target from N/A to N/A for G1 Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of G1 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for G1 Therapeutics was filed on February 28, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
While ratings are subjective and will change, the latest G1 Therapeutics (GTHX) rating was a reiterated with a price target of $0.00 to $12.00. The current price G1 Therapeutics (GTHX) is trading at is $4.41, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.